Medical Minds: Prelaunch and/or Launch of More Than 30 Oncology Products
| Cancer/Cancer Associated | Product |
| Acute lymphoblastic leukemia | Sanofi-Aventis/Oncaspar®; Chiron/cerubidine |
| Acute promyelocytic leukemia | Cell Therapeutics/Trisenox® |
| Breast cancer | Roche/Herceptin®; GSK/Tykerb® |
| Breast cancer diagnostics | Genoptix Medical Laboratory; Monogram Biosciences |
| Bone metastases | Chiron-Novartis/Aredia®; Roche/Bondronat® |
| Cancer-associated anemia | Ortho Biotech/Procrit® |
| Chemotherapy/radiotherapy- induced nausea & vomiting | GSK/Kytril®, RezonicTM (phase 3) |
| Chronic lymphocytic leukemia | GSK/Arzerra® |
| Colon cancer | Cell Pathways/PrevatacTM (phase 3) |
| Hematologic cancer diagnostics | Sequenta |
| High-grade glioma | Tocagen/TOCA 511 & TOCA FC |
| Melanoma | Chiron/Proleukin®; Cancervax/CanvaxinTM (phase 3) |
| Non-Hodgkin lymphoma | Genentech/Rituxan®; Genitope/MyVax®; BiogenIdec/Zevalin®; Cell Therapeutics/pixantrone (phase 3) |
| Non-small cell lung cancer | Cell Therapeutics/XyotaxTM (phase 3) |
| Oncology franchise (corporate) | Agouron-Pfizer; Genentech BioOncology; GSK |
| Ovarian cancer | GSK/Hycamtin® |
| Patient Advocacy: Renal cell carcinoma | National Coalition for Cancer Survivorship/Cancer Survival Toolbox® |
| Small cell lung cancer | Bayer-Onyx/Nexavar®; Chiron/Proleukin®; GSK/VotrientTM |
| Stem cell transplantation | GSK/Hycamtin® |
| Thyroid diagnostics | Amgen/Neupogen®, Amgen Cell Therapy; MGDF, Stemgen® (all phase 3) |
Key Staff Experience:
Lynn Nye, President
Her oncology experience includes 5 years directing prelaunch and launch education and promotion for the US/global launch of Rituxan/MabThera, management of promotion for the global launch of Herceptin, and development of multiple oncology educational programs related to many of the products listed above.
Chuck Dexter, Senior Medical Director
Chuck’s wealth of experience in oncology includes development of communications strategies, medical direction, and writing of educational and promotional materials for most of the products and services listed above.
Art Nagano, Creative Director
In the oncology arena, as well as his work with current Medical Minds clients, Art has developed and implemented campaigns for the US/global launch of Rituxan/MabThera, the global launch of Herceptin, and our 14-year patient advocacy initiative related to the NCCS and the Cancer Survival Toolbox. He directed the repositioning and promotional relaunch of Zevalin for BiogenIDEC.